Key result
The recombinant oncolytic strain RVP3 retained the ability to replicate in and kill tumor cells while losing the ability to effectively replicate in conditionally normal embryonic astrocytes and fibroblasts.
Why the study?
Diffuse gliomas are incurable, prevalent, and aggressive central nervous system tumors, making the development of selective oncolytic viral strains for malignant neoplasms highly relevant.
Does the recombinant oncolytic strain RVP3 demonstrate selective oncolytic activity in tumor cells without replicating in normal cells in vitro?
Does the recombinant oncolytic strain RVP3 demonstrate selective oncolytic activity in tumor cells without replicating in normal cells in vitro?
The recombinant poliovirus strain RVP3 demonstrates selective oncolytic potential in vitro, replicating in tumor cells but not in normal embryonic astrocytes or fibroblasts.
May guide oncolytic virus engineering; leaves open in vivo efficacy and safety.
Diffuse gliomas are incurable, prevalent, and aggressive central nervous system tumors. Therefore, the development of selective oncolytic viral strains for malignant neoplasms is highly relevant. This study aimed to create an oncolytic virus based on a vaccine strain of poliovirus type 3 with natural antitumor activity. To achieve this goal, we replaced the internal ribosome entry site (IRES) of poliovirus with the corresponding fragment of human rhinovirus 30. The resulting recombinant oncolytic strain RVP3 retained the serotype of poliovirus type 3, as confirmed by virus neutralization micro-test with specific antiserum. In addition, the oncolytic efficacy of RVP3 was assessed in vitro on a broad panel of cell cultures. According to the results, RVP3 has changed its tropism, losing the ability to replicate in conditionally normal cell lines of embryonic astrocytes and embryonic fibroblasts while retaining the ability to replicate in tumor cells.
No takes yet. Share an insight, caveat, or question.
Hamad et al. (2022) studied Diffuse glioma. Recombinant oncolytic poliovirus type 3 strain (RVP3) vs. Poliovirus type 3 Sabin vaccine strain (PV3S) was evaluated on Viral replication capacity and cell line sensitivity (cytolytic activity) in vitro. The recombinant oncolytic strain RVP3 retained the ability to replicate in and kill tumor cells while losing the ability to effectively replicate in conditionally normal embryonic astrocytes and fibroblasts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: